Loading...

AnteoTech Limited

ADO.AXASX
Healthcare
Biotechnology
A$0.02
A$0.00(0.00%)

AnteoTech Limited (ADO.AX) Financial Performance & Income Statement Overview

Analyze AnteoTech Limited (ADO.AX) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.

Revenue Growth
25.89%
25.89%
Operating Income Growth
4.38%
4.38%
Net Income Growth
29.82%
29.82%
Operating Cash Flow Growth
19.33%
19.33%
Operating Margin
2115.60%
2115.60%
Gross Margin
100.00%
100.00%
Net Profit Margin
1600.37%
1600.37%
ROE
-134.10%
134.10%
ROIC
-114.51%
114.51%

AnteoTech Limited (ADO.AX) Income Statement & Financial Overview

Analyze AnteoTech Limited’s ADO.AX earnings with segmented quarterly and yearly financial statement figures.

MetricQ2 2025Q4 2024Q2 2024Q4 2023
Revenue$3.15M-$3.70M$379139.00$77941.00
Cost of Revenue$0.00$0.00$33139.00$0.00
Gross Profit$3.15M-$3.70M$346000.00$77941.00
Gross Profit Ratio$1.00$1.00$0.91$1.00
R&D Expenses$1.97M$4.16M$2.11M$960291.00
SG&A Expenses$2.85M$2.00M$3.92M$5.10M
Operating Expenses$4.82M$6.16M$6.02M$6.06M
Total Costs & Expenses$4.82M$6.16M$6.54M$6.63M
Interest Income$0.00$25004.00$29490.00$14059.00
Interest Expense$0.00$0.00$0.00$0.00
Depreciation & Amortization$231394.00$520524.00$519177.00$572351.00
EBITDA-$2.00M-$6.006M-$5.61M-$8.54M
EBITDA Ratio-$0.63$1.62-$14.79-$76.74
Operating Income-$1.67M-$9.86M-$6.16M-$6.55M
Operating Income Ratio-$0.53$2.67-$16.26-$84.08
Other Income/Expenses (Net)-$2.98M$3.34M$36990.00$98887.00
Income Before Tax-$4.64M-$6.53M-$6.13M-$9.11M
Income Before Tax Ratio-$1.47$1.76-$16.16-$116.87
Income Tax Expense-$2.45M$0.00-$3.77M-$1.00
Net Income-$2.19M-$6.53M-$2.35M-$9.11M
Net Income Ratio-$0.70$1.76-$6.21-$116.87
EPS-$0.001-$0.003-$0.001-$0.004
Diluted EPS-$0.001-$0.003-$0.001-$0.004
Weighted Avg Shares Outstanding$2.44B$2.31B$2.14B$2.009B
Weighted Avg Shares Outstanding (Diluted)$2.44B$2.34B$2.14B$2.009B

Over the past four quarters, AnteoTech Limited demonstrated steady revenue growth, increasing from $77941.00 in Q4 2023 to $3.15M in Q2 2025. Operating income reached -$1.67M in Q2 2025, maintaining a consistent -53% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$2.00M, reflecting operational efficiency. Net income rose to -$2.19M, with EPS at -$0.001. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;